FINNENCE ▪ THE WIRE FILE
THE WIRE · № 55477
Company▲ Bullish
Phase 3 results posted: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Seagen Inc.
KINDCompany
DIRECTION▲ Bullish
SOURCES3
ENTITIES1
STORY SIZE3 RECORDS
FIRST SEEN2026-09-29 12:00 UTC
LAST UPDATE2026-09-29 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Posted Phase 3 results for tucatinib in HER2+ breast cancer support Seagen's (Pfizer) oncology combination.
Tucatinib combo data supports HER2 franchise
CATALYST TO WATCH
Regulatory submissions based on the data
MAIN RISK
Trial still active, not fully recruiting
FULL DISPATCH
Sponsor: Seagen Inc.; Status: Active Not Recruiting; Conditions: HER2 Positive Breast Cancer; Interventions: Tucatinib, Trastuzumab, Pertuzumab; Enrollment: 654 (actual); First posted: 2021-11-24; Results posted: 2026-09-29; NCT: NCT05132582
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 3 TIMES · FIRST 2026-09-29 12:00 UTC · LAST 2026-09-29 12:00 UTC2026-09-29 12:00 UTCCompanyPhase 3 results posted: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Seagen Inc.CURRENT RECORD
2026-09-29 12:00 UTCCompanyPhase 3 results posted: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia — Otsuka Pharmaceutical Development & Commercialization, Inc.
2026-09-29 12:00 UTCCompanyPhase 3 results posted: A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age — ModernaTX, Inc.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Phase 3 results posted: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia — Otsuka Pharmaceutical Development & Commercialization, Inc.2026-09-29 12:00 UTC
Phase 3 results posted: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia — Otsuka Pharmaceutical Development & Commercialization, Inc.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age — ModernaTX, Inc.2026-09-29 12:00 UTC
Phase 3 results posted: A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age — ModernaTX, Inc.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Another proposed mega merger: HealthPartners, Essentia Health boards approve plan to combine organizations2026-09-29 15:50 UTC
Another proposed mega merger: HealthPartners, Essentia Health boards approve plan to combine organizations2026-09-29 15:50 UTC
→CORRELATIONshares Healthcare
Health tech's dealmaking boom is back as firms chase scale and profitable growth2026-09-29 16:00 UTC
Health tech's dealmaking boom is back as firms chase scale and profitable growth2026-09-29 16:00 UTC
→CORRELATIONshares Healthcare
Minnesota health systems HealthPartners, Essentia Health announce plan to merge2026-09-29 16:11 UTC
Minnesota health systems HealthPartners, Essentia Health announce plan to merge2026-09-29 16:11 UTC
→CORRELATIONshares Healthcare
ADARx’s $446m IPO signals investor appetite for next-gen RNA therapeutics2026-09-29 11:09 UTC
ADARx’s $446m IPO signals investor appetite for next-gen RNA therapeutics2026-09-29 11:09 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.